Project Grant R21CA301201
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$231K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This $369,108 Project Grant awarded by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) funds research by The Broad Institute, Inc. to investigate the therapeutic potential of intentionally inducing resistance to BRAF and MEK inhibitors in melanoma. The goal is to demonstrate that melanoma cancers which develop resistance to these targeted therapies will become more susceptible to lethal MAPK pathway hyperactivation. The research will employ cellular...
This federal Project Grant award, valued at $1,224,644.00, was provided by the National Cancer Institute (NCI) under its Cancer Biology Research program (CFDA 93.396). The grant is focused on dissecting a novel tumor-promoting axis in intrahepatic cholangiocarcinoma (CCA), a highly desmoplastic and deadly type of bile duct cancer.
The key objectives of this 5-year project, awarded on August 13, 2024, are to: 1) Elucidate the molecular mechanisms by which the immune checkpoint protein B7-H4...
This $687,679 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to characterize the transcriptional regulatory landscape in hepatocellular carcinoma (HCC) and identify novel tumor cell-intrinsic vulnerabilities as potential therapeutic targets.
The research, led by The Trustees of Columbia University in the City of New York, will computationally establish transcriptional master regulators (TMRs) in HCC, confirm their...
The National Cancer Institute (NCI) awarded a $101,856 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to The Trustees of Columbia University in the City of New York to support research on the impact of genomic variants on T cell anti-tumor activity. The grant funding will enable in-depth mechanistic and in vivo functional studies of single-nucleotide variants in genes like PIK3CD and PPP3CA, which have been found to enhance multiple hallmarks of T cell activity and...
This $577,818 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to develop new therapeutic combinations to boost the "abscopal effect" and improve clinical outcomes for patients with advanced cancers. The award supports research at Mayo Clinic to investigate the role of the immune checkpoint molecule B7-H3 in mediating tumor immune evasion, with the goal of overcoming resistance to radiotherapy. The...
This $649,679 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will fund research conducted by The Institute For Cancer Research to investigate a novel strategy for enhancing cancer immunotherapy responsiveness. The project aims to determine if targeting the RNA/DNA helicase DHX9 can induce "viral mimicry" in small cell lung cancer cells, triggering an antiviral immune response and improving the efficacy of immune checkpoint blockade...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), supports innovative research by Cold Spring Harbor Laboratory (CSHL) to define the epigenetic mechanism by which targeting the chromatin regulator BRD8 re-establishes p53-mediated tumor suppression in glioblastoma (GBM) lacking p53 mutations. The key objectives are to: 1) characterize the genomic and epigenomic features of p53 target genes activated by the...
This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), is supporting research aimed at developing effective therapeutic strategies for lung cancers with SMARCA4 genetic deficiencies. The primary grantee, The Trustees of Columbia University in the City of New York, will receive $557,418 over the award period from March 2025 to February 2030. The research will use genetically engineered mouse models to assess the impact of...
This $541,682 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research by the Trustees of Columbia University in New York to better understand the mechanisms underlying the 3D reorganization of the genome in cancer cells following DNA damage. The key objectives are to reveal how DNA repair domains assemble in 3D and evaluate the physiological and pathological consequences of this process, particularly...